
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 29, 2012

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

001-33357
(Commission File Number)

65-0643773
(IRS Employer
Identification No.)

2 Snunit Street
Science Park, POB 455
Carmiel, Israel
(Address of principal executive offices)

20100
(Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure

On May 29, 2012, Protalix BioTherapeutics, Inc. issued a press release announcing that senior management will present at three upcoming conferences. Details regarding the conferences are as follows:

Jefferies 2012 Global Healthcare Conference

Presenter: Mr. Yossi Maimon, Chief Financial Officer

Corporate Presentation

Monday, June 4, 2012 at 1:30 PM EDT

New York, NY

A webcast of this presentation will be available at www.protalix.com on the event calendar page and a replay will be archived and available after the conference for 30 days.

2012 BIO International Convention

Presenter: Dr. David Aviezer, President and Chief Executive Officer

Session titled, "Neither Beast nor Bird: Addressing Biomanufacturing Challenges with New Expression Systems."

Tuesday, June 19, 2012 at 10:00 AM EDT

Room 258B of the Boston Convention & Exhibition Center, MA

Corporate Presentation

Tuesday, June 19, 2012 at 3:45 PM EDT

Room 104A of the Boston Convention & Exhibition Center, MA

Wells Fargo Securities Research & Economics 2012 Healthcare Conference

Presenter: Dr. David Aviezer, President and Chief Executive Officer

Corporate Presentation

Wednesday, June 20, 2012 at 9:30 AM EDT

InterContinental Boston, Boston, MA

A webcast of this presentation will be available at www.protalix.com on the event calendar page and a replay will be archived and available after the conference for 30 days.

A copy of the press release is furnished as Exhibit 99.1.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated May 29, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: May 29, 2012

By: /s/ David Aviezer
Name: David Aviezer, Ph.D.
Title: President and
Chief Executive Officer

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

CARMIEL, Israel, May 29, 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that senior management will present at three upcoming conferences.

Details regarding the conferences are as follows:

Jefferies 2012 Global Healthcare Conference

Presenter: Mr. Yossi Maimon, Chief Financial Officer

Corporate Presentation

Monday, June 4, 2012 at 1:30 PM EDT

New York, NY

A webcast of this presentation will be available at www.protalix.com on the event calendar page and a replay will be archived and available after the conference for 30 days.

2012 BIO International Convention

Presenter: Dr. David Aviezer, President and Chief Executive Officer

Session titled, "Neither Beast nor Bird: Addressing Biomanufacturing Challenges with New Expression Systems."

Tuesday, June 19, 2012 at 10:00 AM EDT

Room 258B of the Boston Convention & Exhibition Center, MA

Corporate Presentation

Tuesday, June 19, 2012 at 3:45 PM EDT

Room 104A of the Boston Convention & Exhibition Center, MA

Wells Fargo Securities Research & Economics 2012 Healthcare Conference

Presenter: Dr. David Aviezer, President and Chief Executive Officer

Corporate Presentation

Wednesday, June 20, 2012 at 9:30 AM EDT

InterContinental Boston, Boston, MA

A webcast of this presentation will be available at www.protalix.com on the event calendar page and a replay will be archived and available after the conference for 30 days.

About Protalix

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first approved product manufactured by ProCellEx, ELELYSO™ (taliglucerase alfa), was approved for marketing by the U.S. Food and Drug Administration on May 1, 2012 and is partnered with Pfizer for worldwide development and commercialization, excluding Israel, where Protalix retains full rights. Marketing applications for taliglucerase alfa have been filed in Europe, Israel, Brazil and Australia. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel(R)) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.

Forward Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "anticipate," "believe," "estimate," "expect" and "intend" and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. The statements in this release are valid only as of the date hereof and we disclaim any obligation to update this information.

Investor Contact

Marcy Nanus
The Trout Group, LLC
646-378-2927
mnanus@troutgroup.com

Media Contact

Jennifer Conrad or Kari Watson
MacDougall Biomedical Communications
781-235-3060
jconrad@macbiocom.com
kwatson@macbiocom.com
